Reiki to support immunotherapy-related fatigue, pain, and stress in adults with cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot interventional project delivers weekly Usui Reiki sessions to adults with cancer who are actively receiving PD‑1 or PD‑L1 immunotherapy and report clinically significant fatigue. Participants continue standard cancer care while receiving Reiki from a trained practitioner, and symptom outcomes such as fatigue, pain, and stress are measured. The trial also examines feasibility outcomes including recruitment, retention, adherence, and acceptability of offering Reiki in the oncology clinic. Reiki is provided as a complementary, non‑invasive supportive practice and is not a replacement for medical treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must be greater than 18 years of age.
* Currently diagnosed with cancer.
* Actively receiving immunotherapy treatment with ICI (PD1 or -PD-L1 inhibitor (single-agent immunotherapy or immunotherapy in combination with other agents; also including the use of steroids if applicable)
* Report clinically significant fatigue over the past 7 days.
* Able to travel to the study site to receive Reiki treatments once a week.
* Understanding and willing to complete all study procedures.
* Capable of giving written informed consent.
* Proficient ability to speak, read, and write in English or Spanish.

Exclusion Criteria:

* Individuals currently receiving or received Reiki treatment in the past 30 days
* Currently diagnosed with a severe psychiatric illness (i.e. schizophrenia, dementia, major depression with suicidal ideations)
* Currently pregnant or intending to become pregnant during the study timeframe

Where it's running

• UCI Health Susan Samueli Integrative Health Institute
  Irvine, California, United States Recruiting
• UCI Health
  Orange, California, United States Recruiting

Study contacts

• Study coordinator: Dalia Kagramanov, PhD
• Email: dkagrama@hs.uci.edu
• Phone: 323-961-2728

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum

  Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07815834

• Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer

  In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07686640

• Nuvastatic for Fatigue in Breast Cancer: A Phase III Trial

  A phase III study will test whether Nuvastatic 300 mg capsules can reduce fatigue in adults with triple-negative metastatic breast cancer receiving first-line chemotherapy.

  Recruiting at 3 sites Phase 3 Natureceuticals Sdn Bhd · Visakhapatnam, Andhra Pradesh and 5 other locations · NCT07669467

• Nuvastatic 300mg Capsule in metastatic colorectal cancer patients on first-line chemotherapy

  This trial tests whether Nuvastatic 300mg capsules can lessen cancer-related fatigue in adults with metastatic colorectal cancer receiving standard first-line chemotherapy, compared with a placebo.

  Recruiting at 6 sites Phase 3 Natureceuticals Sdn Bhd · Visakhapatnam, Andhra Pradesh and 5 other locations · NCT07669454

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.